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Abstract
 
Interleukin (IL)-6 is produced by professional antigen-presenting cells (APCs) such as B cells,
macrophages, and dendritic cells. It has been previously shown that APC-derived IL-6 pro-
motes the differentiation of naive CD4
 
 
 
 T cells into effector T helper type 2 (Th2) cells. Here,
we have studied the molecular mechanism for IL-6–mediated Th2 differentiation. During the
activation of CD4
 
 
 
 T cells, IL-6 induces the production of IL-4, which promotes the differen-
tiation of these cells into effector Th2 cells. Regulation of IL-4 gene expression by IL-6 is me-
diated by nuclear factor of activated T cells (NFAT), as inhibition of NFAT prevents IL-6–
driven IL-4 production and Th2 differentiation. IL-6 upregulates NFAT transcriptional activity
by increasing the levels of NFATc2. The ability of IL-6 to promote Th2 differentiation is im-
paired in CD4
 
 
 
 T cells that lack NFATc2, demonstrating that NFATc2 is required for regula-
tion of IL-4 gene expression by IL-6. Regulation of NFATc2 expression and NFAT transcrip-
tional activity represents a novel pathway by which IL-6 can modulate gene expression.
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Introduction
 
Cytokines can be pleiotropic in a given cell type due, in
part, to the activation of several signaling pathways. IL-6
binds to the surface IL-6 receptor (IL-6R)
 
 
 
, leading to
the dimerization of gp130/IL-6R
 
 
 
 (1). Dimerization of
gp130 by IL-6 causes the activation of two signaling path-
ways: (a) the Janus kinase (JAK)
 
*
 
/signal transducers and
activators of transcription (STAT) pathway and (b) the
CCAAT/enhancer binding protein (C/EBP) pathway.
Activation of the extracellular signal–regulated kinase
(ERK) pathway by IL-6 appears to mediate phosphoryla-
tion and activation of C/EBP
 
 
 
 (NF-IL6; references 2–4).
IL-6 also induces the expression of C/EBP
 
 
 
 (NF-IL6
 
 
 
),
another member of the C/EBP family of transcription fac-
tors (5). C/EBP
 
 
 
 together with C/EBP
 
 
 
 regulate type-1
IL-6 responsive genes (6, 7). Activation of Jak1, 2, and
Tyk2 by IL-6 results in the phosphorylation and activation
of STAT3 and, to much lesser extent, STAT1 leading to
the induction of type-2 IL-6 responsive gene expression
(8–11).
IL-6 is produced by APCs such as B cells, macrophages,
 
and dendritic cells. It can also be secreted by nonprofessional
APCs such as glial, epithelial, endothelial, and some tumor
cells (for a review, see reference 12). IL-6 is crucial for the
acute phase response in hepatocytes, is involved in the
differentiation of B cells and myeloid cells, and induces
growth of osteoblasts, hematopoietic, and neural cells (12).
It has been recently shown that IL-6 can confer multidrug
resistance to breast cancer cells (13).
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Regulation of NFAT Activity by IL-6
 
IL-6 also influences several aspects of the T cell immune
response. This cytokine can act as a survival factor for rest-
ing T cells, but not for activated CD4
 
 
 
 T cells (14, 15).
IL-6 can also protect resting CD8
 
 
 
 T cells from death (16).
We have recently shown that IL-6 inhibits the differentia-
tion of CD4
 
 
 
 T cells into effector Th1 cells. IL-6 induces
the expression of suppressor of cytokine signaling (SOCS)1
which inhibits IFN-
 
  
 
signaling (17). IL-6 also directs the
differentiation of CD4
 
 
 
 T cells into IL-4–producing effec-
tor Th2 cells (18), but the molecular mechanism has not
yet been defined. Whereas the inhibition of Th1 differenti-
ation by IL-6 is IL-4 independent (17), IL-4 is required for
the promotion of Th2 differentiation by IL-6 (18). Thus, it
is likely that IL-6 utilizes two different mechanisms to in-
hibit Th1 differentiation and promote Th2 differentiation.
Here we show that IL-6 promotes Th2 differentiation by
inducing IL-4 gene expression during the activation of
CD4
 
 
 
 T cells. Several studies have shown the presence of
nuclear factor of activated T cells (NFAT) binding motifs
in the IL-4 promoter and the positive role of NFAT in the
regulation of IL-4 gene transcription (19–21). Four mem-
bers of the NFATc family have been described (NFATc1,
c2, c3, and c4). IL-4 production appears to be normal in
mice that lack NFATc3 (22). In contrast, reduced IL-4
production by Th2 cells has been observed in splenocytes
from NFATc1–deficient chimeric mice (23, 24). The role
of NFATc2 in IL-4 regulation is less clear. Although some
studies have reported increased production of IL-4 in the
absence of NFATc2 (25), other studies have shown an ini-
tial decrease in IL-4 synthesis in these mice (26, 27). Dis-
ruption of NFATc2 and NFATc3 results in increased IL-4
production (28), whereas disruption of both NFATc1 and
NFATc2 abrogates production of a large number of cyto-
kines including IL-4 (29).
In this study we show that IL-6 regulates IL-4 gene ex-
pression by activating NFAT. IL-6 induces the specific ex-
pression of NFATc2 mRNA and protein. Examination of
NFATc2–deficient mice revealed that NFATc2 is required
for the induction of IL-4 gene expression and Th2 differ-
entiation by IL-6. Thus, the regulation of NFATc2 expres-
sion by IL-6 represents a novel mechanism by which this
cytokine regulates NFAT-mediated transcription and IL-4
gene expression.
 
Materials and Methods
 
Reagents.
 
Anti-CD3 mAb (145–2C11), anti-CD28 (BD Phar-
Mingen), IL-6 (R&D Systems), IL-4 (R&D Systems), IL-2 (R&D
Systems), IL-5 (R&D Systems), IL-7 (R&D Systems), anti–IL-6
mAb (R&D Systems), anti–IL-4 mAb (BD PharMingen), PMA
(Sigma-Aldrich), and ionomycin (Sigma-Aldrich) were used for
T cell activation and differentiation.
 
Mice.
 
Wild-type B10.BR mice (The Jackson Laboratory)
were used as the source of CD4
 
 
 
 T cells except when indicated.
NFAT-, NF-
 
 
 
B-, and activator protein 1 (AP-1)-luciferase re-
porter transgenic mice in the B10.BR background were used to
determine transcriptional activities (30–33). The dominant nega-
tive (dn)NFAT transgenic mice (34) were backcrossed onto the
B10.BR background. C57Bl/6 NFATc2
 
 
 
/
 
 
 
 mice have been
 
published previously (27). Procedures that involved mice were
approved by institutional guidelines for animal care.
 
Cell Preparation and Activation.
 
Total CD4
 
 
 
 T cells were iso-
lated from spleen and lymph nodes by negative selection as de-
scribed (33) using a combination of anti-MHC class II (m5/115),
anti-CD8 (TIB105), anti-NK1.1 (BD PharMingen), and anti-
Mac1 mAb (BD PharMingen). Isolation of naive CD4
 
 
 
 T cells
was performed by purification of CD4
 
 
 
 T cells by negative selec-
tion, followed by staining with a FITC-conjugated anti-CD4
mAb (BD PharMingen) and a PE-conjugated anti-CD44 (Cal-
tag), and cell sorting. CD4
 
 
 
CD44
 
low
 
 population was isolated as
naive CD4
 
 
 
 T cells. Cells were activated with plate-bound anti-
CD3 (5 
 
 
 
g/ml) and soluble anti-CD28 (1 
 
 
 
g/ml) mAbs in the
presence or absence of the corresponding cytokine. For the gen-
eration of effector Th2 cells, the cells were extensively washed af-
ter four days of activation, and restimulated with plate-bound
anti-CD3 mAb (5 
 
 
 
g/ml) alone for 24 h.
Analysis of naive and memory CD4
 
 
 
 T cells in spleen was per-
formed by staining with a Red613-conjugated anti-CD4, FITC-
conjugated anti-CD45RB, and PE-conjugated anti-CD44 mAbs
and flow cytometry. APCs were generated by treatment of sple-
nocytes with mitomycin C (50 
 
 
 
g/ml) for 50 min at 37
 
 
 
C fol-
lowed by extensive washes.
 
Determination of Cytokine Production.
 
ELISAs were performed
with purified anti–IL-4 mAb (2 
 
 
 
g/ml) as capture antibody,
the corresponding biotinylated anti–IL-4 mAb (1 
 
 
 
g/ml; BD
PharMingen), horseradish peroxidase-conjugated streptavidin
(Sigma-Aldrich), and the TMB microwell peroxidase substrate
and stop solution (Kirkegaard & Perry Labs, Inc.) according to
the recommended protocol (BD PharMingen). Recombinant
mouse IL-4 (R&D Systems) was used as a standard.
 
Ribonuclease Protection Assay.
 
Total RNA was extracted from
cells using Ultraspec RNA Isolation Reagent (Biotecx Labora-
tory) as recommended by the manufacturer. Ribonuclease pro-
tection assay (RPA) was performed using the mCK-1 template
kit (BD PharMingen) according to the manufacturer’s protocol.
Briefly, 3 
 
 
 
g of total RNA was hybridized overnight with
[
 
32
 
P]UTP radiolabeled in vitro transcribed RNA probes. Over-
lapping single stranded (ss)RNA on hybridized double-stranded
(ds)RNAs was digested with RNases A and T1 and the protected
dsRNA duplexes were purified and resolved on urea-denaturing
gels. Gels were dried and exposed to Eastman Kodak Co. 
 
M
 
r
 
 film
for autoradiographic analysis.
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts were pre-
pared from stimulated and unstimulated CD4
 
 
 
 T cells as de-
scribed previously (35, 36). Binding reactions were performed us-
ing 2 
 
 
 
g of nuclear proteins and a [
 
32
 
P]dCTP end-labeled
double-stranded oligonucleotide probe containing an NFAT
binding site from the proximal IL-4 gene promoter (37), an AP-1
binding site from the collagenase gene promoter (38, 39), or a
cAMP response element binding protein (CREB) site from the
somatostatin gene promoter (40). 1 
 
 
 
l of anti-glutathione S-trans-
ferase (GST) Ab, anti-NFATc2 Ab (Upstate Biotechnology), or
anti-NFATc1 mAb (Affinity BioReagents, Inc.) was present dur-
ing the binding reactions for supershift analysis. Samples were
electrophoresed under nondenaturing conditions and exposed to
film for autoradiography.
 
Northern Blot Analysis.
 
Total RNA from CD4
 
 
 
 T cells was
isolated as described above. 10 
 
 
 
g of RNA were separated and
transferred to a nylon membrane. Membranes were hybridized
with a [
 
32
 
P]-labeled mouse NFATc2 cDNA probe (41). Blots
were stripped and reprobed with a 
 
 
 
-actin cDNA probe as a
loading control. 
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Western Blot Analysis.
 
Whole cell lysates were separated by
SDS-PAGE, transferred to membranes, and blotted as described
previously (42) with anti-NFATc2 (Upstate Biotechnology),
anti-NFATc1 (Affinity BioReagents, Inc.), anti-NFATc3 (Santa
Cruz Biotechnology, Inc.), anti–GATA-3 (Santa Cruz Biotech-
nology, Inc.), anti-actin (Sigma-Aldrich), and anti-Flag (M2;
Sigma-Aldrich) Abs.
 
Luciferase Assay.
 
Relative luciferase activity was determined
as described previously (31). Relative light units (RLU) were
measured with a TD 20/20 Luminometer (Turner Designs).
 
Confocal Fluorescence Microscopy.
 
CD4
 
 
 
 T cells were purified
from lymph nodes and spleens and stimulated for 48 h with anti-
CD3 and anti-CD28 mAbs in the presence or absence of IL-6,
cytospun onto slides, and fixed in 3.7% formaldehyde. Slides
were placed in methanol for 10 min at –20
 
 
 
C. Cells were perme-
abilized in 0.1% Triton X-100 for 15 min, blocked in 1% BSA
for 1 h, incubated with either anti-NFATc2 rabbit antiserum
(Upstate Biotechnology), anti-NFATc1 mouse mAb (Affinity
BioReagents, Inc.), or anti-NFATc3 Ab (Santa Cruz Biotechnol-
ogy, Inc.) for 1 h, washed twice in PBS, then incubated with ei-
ther Cy3-conjugated anti–rabbit or anti–mouse secondary mAbs
for 30 min. After washing twice, nuclei were stained with
YOYO-1-iodide (Molecular Probes, Inc.) in PBS with 50 
 
 
 
g/ml
RNase for 5 min. Slides were washed twice in PBS, briefly rinsed
in H
 
2
 
O, allowed to dry, then coverslipped using Vectashield
mounting medium (Vector Laboratories). Images of NFAT ex-
pression were created using a BioRad MRC 1024 confocal
workstation, including an Olympus BX50 fluorescence micro-
scope and LaserSharp scanning software.
 
Results
 
IL-6 Upregulates IL-4 Expression During CD4
 
 
 
 T Cell Ac-
tivation.
 
Previously, we have shown that IL-6 is able to
differentiate naive CD4
 
 
 
 T cells into effector Th2 cells
(18). CD4
 
 
 
 T cells differentiated with anti-CD3 and anti-
CD28 mAbs in the presence of IL-6 for 4 d produced high
levels of IL-4 after restimulation with anti-CD3 mAb (Fig.
1 A). Polarization of Th2 cells by exogenous IL-6 was as
strong as that obtained with exogenous IL-4 (Fig. 1 A). IL-
6–mediated Th2 differentiation, however, is dependent on
endogenous IL-4, as the presence of a neutralizing anti–IL-4
mAb prevents this effect of IL-6 (18).
Figure 1. IL-6 induces IL-4 gene expression and cytokine production in CD4  T cells. (A) CD4  T cells (106 cells/ml) were stimulated with immo-
bilized anti-CD3 mAb (5  g/ml), soluble anti-CD28 mAb (1  g/ml) and medium alone ( ), IL-4 (103 U/ml), or IL-6 (100 ng/ml). After 4 d, cells
were extensively washed and restimulated for 24 h with immobilized anti-CD3 mAb (5  g/ml). Supernatants were analyzed for IL-4 production by
ELISA. (B) CD4  T cells were stimulated with anti-CD3 and anti-CD28 mAbs in the presence or absence of IL-6. Supernatants were harvested and IL-4
production was determined by ELISA at different time points after activation. (C) Total RNA extracted from unstimulated CD4  T cells and from
CD4  T cells stimulated for 3 d with anti-CD3 and anti-CD28 mAbs (anti-CD3/CD28) in the presence or absence of IL-6 was examined by RPA.
mRNA levels for IL-4, IL-10, IL-13, and L32 are shown. (D) RPA analysis of total RNA from unstimulated CD4  T cells or from CD4  T cells stim-
ulated for 48 h in the absence or presence of IL-6 and/or anti–IL-4 mAb (10  g/ml). (E) CD4  T cells were differentiated in the absence ( ), or pres-
ence of IL-4, IL-6, anti–IL-4, anti–IL-4 and IL-4 (anti–IL4/IL-4), or anti–IL-4 and IL-6 (anti–IL4/IL-6). After 4 d, the cells were washed and restimu-
lated with anti-CD3 mAb alone. IL-4 production was determined by ELISA 24 h after restimulation. 
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It was possible that IL-6 directly triggered initial IL-4
production by CD4
 
 
 
 T cells during activation and that the
secreted IL-4 promoted further Th2 differentiation. To ad-
dress this hypothesis we examined the effect of IL-6 on IL-4
production during the activation of CD4
 
 
 
 T cells. We
first measured the levels of IL-4 produced by CD4
 
 
 
 T cells
activated with anti-CD3 and anti-CD28 mAbs for different
periods of time. Although it is difficult to detect IL-4 dur-
ing activation due to its continuous consumption, we ob-
served increased levels of IL-4 production by cells activated
in the presence of IL-6 (Fig. 1 B). Analysis of intracellular
IL-4 staining showed that the presence of IL-6 during the
stimulation of CD4
 
 
 
 T cells also caused an increase in the
number of cells producing IL-4 (data not shown). RPA
was used to examine the effect of IL-6 on IL-4 gene ex-
pression during activation of CD4
 
 
 
 T cells. Increased levels
of IL-4 mRNA were detected in CD4
 
 
 
 T cells stimulated
in the presence of IL-6 compared with those in cells stimu-
lated in the absence of IL-6 (Fig. 1 C).
As the differentiation of Th2 CD4
 
 
 
 T cells by IL-6 was
dependent on the endogenous production of IL-4 by these
cells, we wanted to demonstrate that the induction of early
IL-4 expression by IL-6 did not require endogenous IL-4.
Thus, we examined the effect of IL-6 on early IL-4 gene
expression in the presence of a neutralizing anti–IL-4 mAb.
The increased IL-4 mRNA levels induced by IL-6 were
also observed in the presence of the anti–IL-4 mAb early
during activation (Fig. 1 D). To show the neutralizing ac-
tivity of the anti–IL-4 mAb, we tested its ability to prevent
Th2 differentiation. CD4
 
 
 
 T cells were differentiated in
the presence of IL-4, IL-6, or anti–IL-4 for 4 d and restim-
ulated for 24 h. The presence of the anti–IL-4 mAb abro-
gated both IL-4 and IL-6–mediated Th2 differentiation
(Fig. 1 E). Together, these results demonstrated that IL-6
promotes Th2 differentiation by increasing the production
of IL-4 by CD4
 
 
 
 T cells during their activation. Endoge-
nous IL-4 was, therefore, required for IL-6–mediated Th2
polarization, but induction of IL-4 gene and protein ex-
pression by IL-6 in CD4
 
 
 
 T cells early during activation
did not require endogenous IL-4.
 
IL-6 Induces NFAT-mediated Transcription in CD4
 
 
 
 T
Cells.
 
The 
 
IL-4
 
 gene is regulated by several transcription
factors including NFAT (43). Several NFAT binding sites
have been identified within the proximal murine IL-4 pro-
moter and have been shown to be important for its induc-
tion (19–21). To determine whether IL-6 could regulate
NFAT-mediated transcription, we examined the effect of
IL-6 on NFAT transcriptional activity using CD4
 
 
 
 T cells
isolated from NFAT-luciferase reporter transgenic mice
(30, 31). High levels of NFAT transcriptional activity was
detected in cells stimulated with anti-CD3 and anti-CD28
mAbs in the presence of IL-6 compared with the activity in
cells stimulated in the absence of IL-6 (Fig. 2 A). The in-
creased NFAT activity (4–6-fold) was not due to an in-
creased number of cells, as we observed only a slight
increase (15–20%) in cell viability in the presence of IL-6
(Fig. 2 B). Unlike NFAT, IL-6 only caused a marginal in-
crease in NF-
 
 
 
B– and AP-1–mediated transcription (15–
Figure 2. Regulation of NFAT transcriptional
activity by IL-6. (A) 5   105 CD4  T cells from
NFAT-luciferase reporter transgenic mice were
stimulated with anti-CD3 and anti-CD28 mAbs in
the presence or absence of IL-6. Relative luciferase
activity was measured at different periods of stimu-
lation. (B) Viability of CD4  T cells stimulated as
in panel A was determined by Trypan Blue exclu-
sion. (C) CD4  T cells from AP-1- or NF- B-
luciferase reporter transgenic mice were stimulated
as in panel A and luciferase activity was determined
after 48 h. (D) Naive CD4 CD44low T cells were
isolated from NFAT-luciferase mice by cell sorting.
4   105 cells were stimulated with anti-CD3 and
anti-CD28 mAbs for 48 h in the absence ( ) or
presence of IL-6 or IL-4 and relative luciferase ac-
tivity was determined.43 Diehl et al.
20%; Fig. 2 C), showing the specific effect of IL-6 on
NFAT-mediated transcription.
To show that the activation of NFAT by IL-6 was not
due to a potential effect of this cytokine on a select subpop-
ulation of CD4  T cells (e.g., memory cells), we examined
the NFAT activity in a purified naive population. Naive
CD4  T cells from NFAT-luciferase transgenic mice were
isolated by cell sorting, stimulated in the presence or ab-
sence of IL-6 and luciferase activity was determined after
48 h. IL-6 also caused a marked induction of NFAT-medi-
ated transcription in purified naive CD4  T cells (Fig. 2
D). Thus, IL-6 specifically enhanced NFAT-mediated
transcription during the activation of naive CD4  T cells,
suggesting that IL-6 regulates IL-4 gene expression by in-
creasing NFAT activity.
NFAT Is Regulated by IL-6 Produced by APCs, but Not by
IL-4. We have shown that early induction of IL-4 expres-
sion by IL-6 is independent of endogenous IL-4 (Fig. 1 D).
To test whether regulation of NFAT by IL-6 was also inde-
pendent of IL-4, we examined the effect of a neutralizing
anti–IL-4 mAb on NFAT transcriptional activity. CD4  T
cells from NFAT-luciferase reporter transgenic mice were
stimulated with anti-CD3 and anti-CD28 mAbs for differ-
ent periods of time in the absence or presence of IL-6 and
an anti–IL-4 mAb. The presence of the anti-IL4 mAb did
not prevent activation of NFAT by IL-6 (Fig. 3 A). How-
ever, the anti-IL4 mAb completely abrogated the effect of
IL-6 on GATA-3 (Fig. 3 B), a Th2-specific transcription
factor involved in the regulation of IL-4 expression (44).
Thus, activation of NFAT by IL-6 represented an early
event independent of IL-4, while upregulation of GATA-3
by IL-6 is an indirect effect mediated by endogenous IL-4.
To further confirm that NFAT-driven transcription was not
regulated by IL-4, CD4  T cells from NFAT-luciferase
transgenic were stimulated in the presence or absence of
IL-4 for 2 or 3 d and luciferase activity was assayed. In con-
trast to IL-6, IL-4 did not increase NFAT transcriptional
activity (Fig. 3 C). Similar results were obtained in purified
naive CD4  T cells (data not shown). We also tested the ef-
fect of other Th2 cytokines (e.g., IL-5) and T cell growth
factors (IL-2 and IL-7) on NFAT transcriptional activity.
None of these cytokines enhanced transcription mediated
by NFAT (Fig. 3 D). Moreover, no effect on NFAT tran-
scriptional activity by Th1-related cytokines (e.g., IL-12
and IFN- ) was detected (data not shown). Thus, IL-6 spe-
cifically regulated NFAT activation.
IL-6 is produced by professional APCs such as macro-
phages, B cells, dendritic cells, and nonprofessional APCs
such as epithelial, endothelial, and some tumor cells (12).
We examined whether physiological levels of IL-6 pro-
duced by accessory cells contributed to NFAT activation.
CD4  T cells from the NFAT-luciferase transgenic mice
were stimulated with a soluble anti-CD3 mAb and wild-
type APCs in the presence or absence of a neutralizing
anti–IL-6 mAb. The presence of the anti-IL-6 mAb caused
a dramatic reduction of NFAT transcriptional activity in
Figure 3. Regulation of NFAT by IL-6 is indepen-
dent of IL-4. (A) 5   105 NFAT-luciferase CD4  T
cells were stimulated with anti-CD3 and anti-CD28
mAbs and medium alone ( ), IL-6, anti–IL-4 mAb, or
IL-6 and anti–IL-4- mAb (IL-6/anti–IL4) and lu-
ciferase activity was measured 48 h later. (B) CD4  T
cells were stimulated in the presence of medium ( ),
IL-4, IL-6, anti–IL-4 mAb, or IL-6 and anti–IL-4 mAb
for 2 d. GATA-3 expression was determined by West-
ern blot using whole cell extracts. Blots were stripped
and reprobed for actin. (C) CD4  T cells from NFAT-
luciferase transgenic mice were stimulated with anti-
CD3 and anti-CD28 mAbs in the presence of medium
alone ( ), IL-6, or IL-4. After 2 or 3 d, relative lu-
ciferase activity was measured. (D) NFAT- luciferase
CD4  T cells were stimulated with anti-CD3 and anti-
CD28 mAbs in the presence of medium alone ( ), IL-2 (25 U/ml), IL-5 (100 ng/ml), or IL-7 (100 ng/ml). Relative luciferase activity was determined
after 36 or 48 h. (E) 5   105 CD4  T cells from NFAT luciferase transgenic mice were stimulated with soluble anti-CD3 mAb (1  g/ml) and wild-type
splenic APCs (2   105 cells) in the presence or absence of a neutralizing anti–IL-6 mAb (10  g/ml). Relative luciferase activity was then measured after
36 or 48 h.44 Regulation of NFAT Activity by IL-6
stimulated CD4  T cells (Fig. 3 D). Thus, APC-derived
IL-6 largely contributed to the regulation of NFAT during
the activation of CD4  T cells.
Inhibition of NFAT Prevents IL-6–induced Th2 Differentia-
tion. To demonstrate that NFAT activation was required
for IL-6–mediated Th2 differentiation we used transgenic
mice expressing a dominant negative form of NFAT (dn-
NFAT) that suppresses NFAT transcriptional activity, but
not the activity of other transcription factors such as AP-1
or NF- B (34). Although expression of this transgene is
driven by the proximal lck promoter, two lines of dnNFAT
transgenic mice (no. 4 and no. 7) also expressed dnNFAT
in CD4  T cells (Fig. 4 A). To test whether expression of
dnNFAT could inhibit activation of NFAT in CD4  T
cells we examined NFAT DNA binding activity in nuclear
extracts from dnNFAT transgenic and negative litter-
mate control cells by electrophoretic mobility shift assay
(EMSA). Levels of NFAT DNA binding were dramatically
reduced (70–90%) in activated CD4  T cells from dn-
NFAT mice compared with the levels in cells from nega-
tive littermate control mice (Fig. 4 B). DNA binding activ-
ity of CREB was also examined as a control (Fig. 4 B). We
also examined the effect of dnNFAT on NFAT-mediated
transcription using CD4  T cells isolated from NFAT-
luciferase transgenic and NFAT-luciferase   dnNFAT
doubly transgenic mice. The presence of dnNFAT blocked
NFAT transcriptional activity in CD4  T cells from dou-
bly transgenic mice that were stimulated with PMA and
ionomycin (Fig. 4 C). Moreover, the expression of dn-
NFAT prevented the enhancement of NFAT transcrip-
tional activity by IL-6 in CD4  T cells stimulated with
anti-CD3 and anti-CD28 mAbs (Fig. 4 D).
The percentage and number of CD4  and CD8  T cells
present in lymph nodes and spleen were similar in dnNFAT
transgenic mice compared with control mice (data not
shown). There was also a normal distribution of naive
Figure 4. Expression of dnNFAT
inhibits IL-6–driven IL-4 produc-
tion and Th2 differentiation. (A)
Whole extracts were isolated from
CD4  T cells from negative litter-
mate control (NLC) and lines no. 4
and no. 7 of dnNFAT transgenic
(Tg ) mice. Expression of the dn-
NFAT transgene was analyzed by
Western blotting using an Ab di-
rected against the Flag tag on dn-
NFAT. (B) CD4  T cells from
negative littermate control (NLC)
or dnNFAT transgenic mice (Tg )
were stimulated for 12 h with anti-
CD3 and anti-CD28 mAbs. Nu-
clear extracts were prepared and
analyzed for NFAT (top panel) and
CREB (bottom panel) DNA bind-
ing activity by EMSA. (C) CD4 
T cells were isolated from NFAT-
luciferase    dnNFAT doubly
transgenic (Tg ) mice and NFAT-
luciferase single transgenic (NLC) mice. 5   105 CD4  T cells were stimulated with PMA (5 ng/ml) and ionomycin (250 ng/ml) and luciferase activity
was measured after 24 or 36 h. (D) NFAT luciferase activity was measured in 5   105 CD4  T cells from NFAT-luciferase   dnNFAT doubly trans-
genic (Tg ) mice or NFAT-luciferase transgenic (NLC) mice stimulated for 2 d with anti-CD3 and anti-CD28 mAbs in the presence or absence of IL-6.
(E) CD4  T cells were purified from negative littermate control (NLC) or dnNFAT transgenic mice (Tg ), stained with anti-CD4, CD44, and
CD45RB mAbs and analyzed by flow cytometry. Dot plots represent the CD44/CD45RB distribution in gated CD4  T cells. (F) Cytokine mRNA lev-
els were analyzed by RPA in CD4  T cells from negative littermate control (NLC) and dnNFAT (Tg ) mice that were stimulated with anti-CD3 and
anti-CD28 mAbs for 3 d in the presence or absence of IL-6. (G) CD4  T cells from negative littermate control (NLC) or dnNFAT (Tg ) mice were
stimulated for 4 d with anti-CD3 and anti-CD28 mAbs in the presence or absence of IL-6, washed, and restimulated with anti-CD3 mAb alone for 24 h
IL-4 production in supernatants was determined by ELISA. WT, wild-type.45 Diehl et al.
(CD44lowCD45RBhigh) and memory (CD44highCD45RBlow)
CD4  T cells in dnNFAT transgenic mice (Fig. 4 E). Fur-
thermore, the expression of dnNFAT did not significantly
affect the proliferation of CD4  T cells (data not shown).
We therefore addressed whether inhibition of NFAT pre-
vented the induction of IL-4 gene expression by IL-6.
CD4  T cells from negative littermate control or dnNFAT
transgenic mice were stimulated in the presence or absence
of IL-6 for 2 d and total RNA was analyzed for cytokine
gene expression by RPA. In contrast to wild-type CD4  T
cells, IL-6 was unable to induce IL-4 gene expression in ac-
tivated CD4  T cells from dnNFAT mice (Fig. 4 F). Upreg-
ulation of IL-10 and IL-13 gene expression by IL-6 was also
inhibited in dnNFAT transgenic CD4  T cells. Notably, the
inhibition of IFN-  gene expression by IL-6 that we have
described previously (17) was not affected in dnNFAT
CD4  T cells (Fig. 4 F), suggesting that IL-6 utilizes separate
pathways to inhibit Th1 and promote Th2 differentiation.
To determine whether NFAT was required for induc-
tion of Th2 polarization by IL-6, we examined the ability
of IL-6 to promote Th2 differentiation in dnNFAT trans-
genic mice. CD4  T cells were isolated from negative lit-
termate control or dnNFAT transgenic mice, stimulated in
the presence or absence of IL-6 for 4 d, and restimulated
for 24 h with anti-CD3 mAb alone. Effector CD4  T cells
from negative littermate control mice that were differenti-
ated with IL-6 produced large amounts of IL-4 (Fig. 4 G),
while IL-6–mediated Th2 differentiation was abrogated in
CD4  T cells from two lines of dnNFAT transgenic mice
(Fig. 4 G). The presence of dnNFAT, however, only
caused a partial inhibition of Th2 differentiation by exoge-
nous IL-4 (data not shown). Thus, NFAT plays a critical
role for the upregulation of IL-4 gene expression by IL-6
early during activation, but other transcription factors (e.g.,
GATA3, c-maf) are likely to be more important for further
IL-4–driven Th2 differentiation.
IL-6 Selectively Induces the Expression of NFATc2 in CD4 
T Cells. To understand the molecular mechanism by
which IL-6 regulates NFAT activity, we examined NFAT
DNA binding using nuclear extracts from CD4  T cells
stimulated with anti-CD3 and anti-CD28 mAbs in the
presence or absence of IL-6. The levels of NFAT nuclear
complexes found in CD4  T cells activated in the presence
of IL-6 were substantially higher compared with those in
cells activated in the absence of IL-6 (Fig. 5 A). In contrast,
the levels of CREB or AP-1 DNA binding were not sig-
nificantly affected by IL-6 (Fig. 5 A). The relative abun-
dance of NFATc2 and NFATc1 in the NFAT nuclear
complexes from cells stimulated in the presence or absence
of IL-6 was determined by supershift analysis using specific
NFAT Abs. An anti-NFATc2 Ab prevented DNA binding
of nuclear NFAT complexes from cells stimulated in the
presence of IL-6 while an anti-NFATc1 Ab had a lesser ef-
fect (Fig. 5 B). These results suggested that NFATc2 was
the predominant component of NFAT complexes in cells
activated in the presence of IL-6.
To confirm the selective nuclear accumulation of
NFATc2 in cells activated in the presence of IL-6 we ex-
amined the expression of NFATc2 by confocal micros-
copy. Increased nuclear levels (yellow color) of NFATc2
were found in CD4  T cells stimulated in the presence of
IL-6. Interestingly, the cytoplasmic levels (red color) of
NFATc2 in CD4  T cells stimulated in the presence of IL-6
were also higher than those in cells activated in the absence
of IL-6 (Fig. 5 C). IL-6 did not significantly affect the levels
of NFATc1 or NFATc3 (Fig. 5 C). Moreover, NFATc2
levels were not affected by IL-4 (Fig. 5 C). Together, these
results suggested that the selective nuclear accumulation of
NFATc2 induced by IL-6 could be due to an up-regula-
tion of NFATc2 expression.
We examined NFATc2 protein levels by Western blot
analysis using whole extracts. CD4  T cells stimulated in
the presence of IL-6 contained higher levels of NFATc2
compared with those stimulated in the absence of IL-6
(Fig. 5 D). The more diffuse (faster moving) NFATc2 band
in cells stimulated in the presence of IL-6 suggested that
there were increased levels of dephosphorylated (i.e., nu-
clear) NFATc2 in these cells. In contrast, the levels of
NFATc1 were not affected by IL-6 (Fig. 5 D), and the
marginal increase in NFATc3 levels was not consistent
among experiments (Fig. 5 D).
To address whether the elevated levels of NFATc2 were
due to an increase of NFATc2 gene expression, we ana-
lyzed NFATc2 mRNA levels by Northern blot. In corre-
lation with increased NFATc2 protein expression, high
NFATc2 mRNA levels were found in CD4  T cells acti-
vated in the presence of IL-6, while low levels of NFATc2
mRNA were detectable in CD4  T cells stimulated in the
absence of IL-6 (Fig. 5 E). Together, these results showed
that IL-6 increased the levels of NFATc2 mRNA and pro-
tein in CD4  T cells during activation, suggesting that
NFATc2 could be responsible for IL-6–induced Th2 dif-
ferentiation.
NFATc2 Is Required for IL-6–mediated Th2 Differentia-
tion. To establish whether NFATc2 was indeed required
for IL-6 to induce IL-4 expression and Th2 differentiation,
we analyzed CD4  T cells lacking NFATc2 (NFATc2 / ).
We first examined whether NFATc2 was required for in-
duction of early IL-4 gene expression by IL-6. CD4  T
cells from wild-type and NFATc2 /  mice were stimu-
lated for 2 d in the absence or presence of IL-6. IL-4
mRNA levels were strongly induced (sixfold) by IL-6 in
wild-type CD4  T cells (Fig. 6 A). However, the presence
of IL-6 did not cause a substantial increase in IL-4 mRNA
(twofold) in NFATc2 /  CD4  T cells (Fig. 6 A). Thus,
IL-6–induced IL-4 gene expression requires NFATc2. The
elevated expression of IL-4 in NFATc2 /  CD4  T cells
compared with wild-type cells stimulated in the absence of
IL-6 correlated with previous observations (25, 26). These
increased levels of IL-4 in CD4  T cells lacking NFATc2
might be due to compensation by other NFATc family
members. We observed increased levels of NFATc1 and
NFATc3 in NFATc2 /  CD4  T cells (Fig. 6 B). Interest-
ingly, IL-6 did not affect NFATc1 or NFATc3 levels in
NFATc2 /  CD4  T cells, supporting the specific effect of
IL-6 on NFATc2.46 Regulation of NFAT Activity by IL-6
We examined whether the lack of NFATc2 interfered
with the differentiation of CD4  T cells into effector Th2
cells by IL-6. CD4  T cells were isolated from wild-type
mice and NFATc2 /  mice (27), differentiated in the
absence or the presence of IL-6, and then restimulated.
Whereas IL-6 promoted strong Th2 differentiation in
wild-type CD4  T cells (60-fold induction of IL-4 produc-
tion), the ability of IL-6 to promote Th2 differentiation of
NFATc2 /   CD4  T cells was severely compromised
(fivefold induction of IL-4 production; Fig. 6 C). Thus, we
conclude that NFATc2 is required for complete Th2 dif-
ferentiation by IL-6.
Discussion
IL-6 is produced by several cell types including macro-
phages, dendritic, B, epithelial, endothelial, and some tu-
mor cells and is involved in a diversity of biological pro-
cesses (for a review, see reference 12). Its pleiotropic
character is probably due to its ability to regulate several
signaling pathways and transcription factors that control the
expression of a number of genes. Previously, we have
shown that IL-6 can differentiate CD4  T cells into effec-
tor Th2 cells, but this differentiation is dependent on en-
dogenous IL-4 (18). In the current study we have investi-
gated the molecular mechanism of Th2 differentiation by
IL-6. We show that IL-6 induces the expression of IL-4 in
CD4  T cells during activation. Regulation of IL-4 ex-
pression by IL-6 is mediated by activation of NFAT since
inhibition of NFAT abrogates this effect of IL-6 on IL-4.
The JAK/STAT3 and the mitogen-activated protein
(MAP) kinase/C/EBP are the two major signaling path-
ways triggered by IL-6 (12, 45). Regulation of NFAT rep-
resents a novel signaling pathway by which IL-6 can exert
Figure 5. IL-6 induces NFATc2
expression. (A) Nuclear extracts
were prepared from unstimulated
CD4  T cells or from CD4  T
cells that were stimulated with
anti-CD3 and anti-CD28 mAbs in
the presence of absence of IL-6 for
2 d. Extracts were incubated with
a double-stranded oligonucleotide
containing the NFAT (top panel),
AP-1 (middle panel), or CREB
(bottom panel) binding sequence
and DNA binding complexes were
resolved by EMSA. (B) CD4  T
cells were stimulated with anti-
CD3 and anti-CD28 mAbs in the
presence or absence of IL-6. After
2 d nuclear extracts were prepared
and NFAT and AP-1 DNA bind-
ing activity was determined by
EMSA. Binding reactions were
performed in the presence of con-
trol anti-GST Ab (CT), anti-
NFATc2 (c2) Ab, or anti-
NFATc1 (c1) mAb. (C) NFATc2
(left panels), NFATc1 (middle
panels), and NFATc3 (right pan-
els) expression in CD4  T cells
stimulated for 2 d in the absence or
presence of IL-6 or IL-4 was de-
termined by confocal microscopy
using specific anti-NFAT Abs and
the DNA marker YOYO for nu-
clear detection. Green color represents YOYO, red color indicates NFAT staining, and yellow color indicates colocalization of YOYO and NFAT
(40 ). (D) CD4  T cells were stimulated with anti-CD3 and anti-CD28 mAbs in the presence or absence of IL-6 for 2 d. Whole cell extracts were pre-
pared and examined for NFATc2, NFATc1, and NFATc3 protein levels by Western blot. Blots were stripped and reprobed for determination of
NFATc1 and NFATc3 expression. (E) Northern blot analysis of NFATc2 gene expression using total RNA from unstimulated CD4  T cells and cells
stimulated in the presence or absence of IL-6.  -actin expression was examined as a loading control.47 Diehl et al.
some of its functions. Upregulation of NFAT activity by
IL-6 appears to be due to the induction of NFATc2 ex-
pression since the levels of NFATc1 and NFATc3 were
not affected by this cytokine. NFATc2 was originally iden-
tified as a preexisting (NFATp) cytoplasmic transcription
factor that is dephosphorylated and translocated into the
nucleus of T cells in response to increased levels of intracel-
lular Ca2  (41). Whereas expression of NFATc1 is induc-
ible in splenocytes and thymocytes after short treatment
with PMA and ionomycin (46), no changes in NFATc2
levels have been previously reported. We now show that
expression of NFATc2 increases during the activation of
CD4  T cells (Fig. 5 D) and IL-6 highly upregulates the
levels of both mRNA and protein (Fig. 5, D and E). Un-
like IL-6, other cytokines such as IL-4, IL-5, IL-2, IL-7,
IL-12, and IFN-  do not affect NFAT levels, indicating
that NFATc2 expression is induced by specific signals trig-
gered by IL-6. The regulation of NFATc2 gene expression
by IL-6 could be mediated by C/EBP since potential C/EBP
binding sites are present in the promoter of the human
NFATc2 gene (unpublished data). Thus, regulation of IL-4
gene expression by IL-6 might be indirectly mediated by
specific C/EBP family members. Induction of IL-4 gene
expression by exogenous IL-4 also appears to be mediated
by an indirect mechanism. IL-4 activates STAT6 which, in
turn, induces the expression of GATA-3 (47).
IL-6 also induces expression of GATA-3. However,
while the effect of IL-6 on NFATc2 expression is inde-
pendent of endogenous IL-4, induction of GATA-3 ex-
pression by IL-6 is requires IL-4. We propose that during
the early stages of the immune response, IL-6 derived from
professional or nonprofessional APCs enhances NFAT ac-
tivity in naive CD4  T cells leading to an upregulation of
endogenous IL-4 gene expression. IL-4 then increases the
expression of GATA-3 for complete Th2 differentiation
(Fig. 6 D).
The role of NFATc2 in the regulation of IL-4 gene tran-
scription is somewhat controversial. Several studies have
shown that NFATc2 can bind to NFAT motifs within the
proximal IL-4 promoter and control its activity in T cells
(19–21). In addition, NFATc2 binds to several regulatory
elements within a specific 3  IL-4 enhancer (48) and
DNase I hypersensitivity sites located within the spacer re-
gion between the IL-4 and IL-13 genes (49). Due to the
aberrant IL-4 expression in lymphoid cells from mice lack-
ing NFATc2, it has been proposed that NFATc2 might be
a negative regulator of IL-4 expression and Th2 effector
function (25, 28). However, other studies show that in the
initial phase of activation, synthesis of IL-4 mRNA is re-
duced in lymphoid cells from NFATc2-deficient mice (26,
27). We have observed that effector CD4  T cells that lack
NFATc2 contain higher levels of NFATc1 and NFATc3
compared with wild-type cells (Fig. 6 B), probably to com-
pensate for the lack of NFATc2. Thus, it is likely that the
increased levels of these two NFAT members may be re-
sponsible for the increased expression and production of
IL-4 in NFATc2 /  mice. In correlation, IL-4 production
is completely abolished in CD4  T cells lacking NFATc1
and NFATc2 (29). Here we show that increased levels of
NFATc2 induced by IL-6 early during activation correlate
with increased NFAT transcriptional activity and IL-4 pro-
duction in CD4  T cells. These results support a positive
Figure 6. NFATc2 is required for IL-6–mediated
Th2 differentiation. (A) Total RNA from wild-type
(WT) or NFATc2-deficient (NFATc2 / ) CD4  T
cells that were stimulated for 2 d in the presence or
absence of IL-6 was subjected to RPA analysis. (B)
NFATc1 and NFATc3 protein levels were deter-
mined by Western blot analysis of whole cell lysates
from wild-type and NFATc2 /  CD4  T cells stim-
ulated for 4 d in the presence or absence of IL-6. Ac-
tin is shown as a loading control. (C) CD4  T cells
from wild-type or NFATc2 /  mice were stimulated
for 4 d with anti-CD3 and anti-CD28 mAbs in the
absence ( ) or presence of IL-6. After 4 d cells were
washed, restimulated with anti-CD3, and IL-4 pro-
duction was determined after 24 h. Results are repre-
sentative of three experiments. (D) NFAT-mediated
differentiation of Th2 cells by IL-6.48 Regulation of NFAT Activity by IL-6
regulatory role for NFATc2 in IL-4 gene expression. More
importantly, the ability of IL-6 to promote Th2 differentia-
tion was largely impaired in the absence of NFATc2, indi-
cating that NFATc2 is indeed required for regulation of
IL-4 by IL-6.
In addition to its role in promoting Th2 differentiation,
we have recently shown that IL-6 inhibits Th1 differentia-
tion (17). Whereas differentiation of Th2 by IL-6 is de-
pendent on endogenous production of IL-4, inhibition of
Th1 differentiation by IL-6 is not. IL-6 inhibits Th1 dif-
ferentiation by interfering with IFN-  signaling through
up-regulation of SOCS1. In the absence of SOCS1, IL-6
fails to inhibit Th1 differentiation, but it retains its ability
to drive Th2 differentiation (17). In this study we show
that IL-6 promotes Th2 differentiation by activating
NFAT which induces endogenous IL-4 gene expression.
Activation of NFAT, however, is not required for inhibi-
tion of IFN-  gene expression and Th1 differentiation by
IL-6 (Fig. 4 G). IL-6 therefore is a key element in the reg-
ulation of the Th1/Th2 balance, as it is able to promote
Th2 differentiation and inhibit Th1 differentiation by two
independent molecular mechanisms involving different
signaling pathways.
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